Spago Nanomedical - SE0004899474
Seite 1 von 1 Neuester Beitrag: 31.07.23 11:35 | ||||
| Eröffnet am: | 04.07.23 18:07 | von: SOGN | Anzahl Beiträge: | 5 |
| Neuester Beitrag: | 31.07.23 11:35 | von: SOGN | Leser gesamt: | 1.242 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Hier mal eine Vorstellung einer schwedischen Biotechfirma. Länger bestehend, aber nun endlich scheint sich einiges zu tun. Ich persönlich habe mal eine kleine vorsichtige Position auf der Börse Stockholm gekauft (in Frankfurt zu wenig los)
Spago Nanomedical
https://spagonanomedical.se/
Vorteile:
+ 2 Produkte, die beide in der klinischen Phase sind (Phase I und IIa)
+ Produkt bereits im Tiermodell wirksam
+ GMP-Herstellung gerade abgeschlossen
+ Große Chance auf Vervielfachung des Kurses (siehe RedEye-Bericht darunter)
RedEye-Seite: https://www.redeye.se/research/873644/...cal-tumorad-in-the-spotlight
Bericht: https://www.redeye.se/api/articles/download-file/...f80-45fc014450a7)
Nachteile:
- Risiko, falls klinische Studien fehlschlagen
- Finanzierung bis Q1 2024 gegeben, eine Kapitalerhöhung ist nicht auszuschließen, wenn sich kein Geldgeber bis dahin findet
- Liquidität der Aktie noch in den Anfangszeiten
Produkte (Einzelheiten zu Produkten kommen in späteren Threads):
* SN132D: Diagnostik für solide Tumore und Endometriosis -> Potential: 150 Mio Dollar
* SN201 (Tumorad): Therapie für solide Tumore -> Potential: 400 Mio Dollar
Marktkapital im Moment um die 5 Mio Euro
Denke mit einer kleinen vorsichtigen Position ist man sicher dabei ohne was zu verpassen. Das denke ich zumindest mir. Natürlich keine Handelsempfehlung.
Wissenschaftliche Publikation Anfang des Jahres veröffentlicht:
Spago Nanomedical publishes scientific paper on positive preclinical data with Tumorad® as treatment of solid tumors
Spago Nanomedical AB (publ) today announced the publication of data on the composition, stability, and mode of action for its leading candidate drug 177Lu-SN201. The preclinical results shows that the candidate drug accumulates favorably in tumors, inhibits tumor growth, provides prolonged survival compared to control, and is suitable for systemic treatment of cancer. The paper was published in the scientific journal ACS Omega.
Publikation:
https://pubs.acs.org/doi/pdf/10.1021/acsomega.2c06755
Spago Nanomedical AB (publ) announces today that a preliminary analysis of data from the phase IIa clinical study SPAGOPIX-02 shows that SN132D has a good safety profile in patients with endometriosis. Further evaluation of the MRI contrast enhancing properties, particularly in lesions indicative of deep endometriosis, is ongoing.
SPAGOPIX-02 is an open-label, proof-of-concept study to evaluate the safety and MRI-enhancing properties of SN132D in patients with suspected endometriosis. The first preliminary results have been compiled and analysed by the study Data Monitoring Committee. It was concluded SN132D is well tolerated in patients with endometriosis and that further analysis is needed before conclusions about efficacy can be made. The Committee further concluded the number of recruited patients (n=8) at this point is sufficient to provide for a meaningful assessment and recruitment is therefore paused.
“We are pleased SN132D continues to show good safety, which is important for all development programs involving our platform material. We look forward to the conclusions of the full analysis of the study results so far which will provide an important basis for decision on further development of the program” says Mats Hansen, CEO of Spago Nanomedical.
The contrast agent SN132D has previously been evaluated in the phase I clinical study SPAGOPIX-01 in patients with confirmed breast cancer. Initial results from the study show that SN132D is well tolerated and provides clear contrast in MRI images of solid tumors in the breast, as well as in the pancreas and liver. Final report of the study is in preparation.
https://spagonanomedical.se/mfn_news/...-phase-iia-study-spagopix-02/